137 related articles for article (PubMed ID: 12812176)
1. Court papers suggest scale of drug's use: lawsuit says doctors were paid endorsers.
Petersen M
N Y Times Web; 2003 May; ():C1, C2. PubMed ID: 12812176
[No Abstract] [Full Text] [Related]
2. Doctor explains why he blew the whistle.
Petersen M
N Y Times Web; 2003 Mar; ():C1, C2. PubMed ID: 12812161
[No Abstract] [Full Text] [Related]
3. Pfizer to pay $430 million over promoting drug to doctors.
Harris G
N Y Times Web; 2004 May; ():C6. PubMed ID: 15290803
[No Abstract] [Full Text] [Related]
4. Pfizer pleads guilty, but drug sales continue to soar.
Lenzer J
BMJ; 2004 May; 328(7450):1217. PubMed ID: 15155480
[No Abstract] [Full Text] [Related]
5. Drug maker to pay $430 million in fines, civil damages.
FDA Consum; 2004; 38(4):36-7. PubMed ID: 15346583
[TBL] [Abstract][Full Text] [Related]
6. Intended and unintended consequences of the gabapentin off-label marketing lawsuit among patients with bipolar disorder.
Chace MJ; Zhang F; Fullerton CA; Huskamp HA; Gilden D; Soumerai SB
J Clin Psychiatry; 2012 Nov; 73(11):1388-94. PubMed ID: 23146199
[TBL] [Abstract][Full Text] [Related]
7. Pfizer versus Kaiser: insurers want their day in court.
Silverman E
BMJ; 2013 Jun; 346():f3738. PubMed ID: 23760967
[No Abstract] [Full Text] [Related]
8. The Neurontin legacy--marketing through misinformation and manipulation.
Landefeld CS; Steinman MA
N Engl J Med; 2009 Jan; 360(2):103-6. PubMed ID: 19129523
[No Abstract] [Full Text] [Related]
9. Results of drug trials can mystify doctors through omission: some professional groups demand public listing of all test outcomes.
Meier B
N Y Times Web; 2004 Jul; ():C1, C3. PubMed ID: 15290807
[No Abstract] [Full Text] [Related]
10. Dicing with death : there's a good chance that the pills your doctor prescribed will do you no good and might even harm you.
Muir H
New Sci; 2006 Jul 29-Aug 4; 191(2562):38-41. PubMed ID: 17115486
[No Abstract] [Full Text] [Related]
11. Gabbing about gabapentin.
Nat Rev Drug Discov; 2003 Apr; 2(4):254. PubMed ID: 12680367
[No Abstract] [Full Text] [Related]
12. The truth is out there.
Lancet Neurol; 2003 May; 2(5):261. PubMed ID: 12849163
[No Abstract] [Full Text] [Related]
13. Pharmaceutical promotion and First Amendment rights.
Troy DE; Gottlieb S
N Engl J Med; 2008 Jul; 359(5):536; author reply 536-7. PubMed ID: 18669437
[No Abstract] [Full Text] [Related]
14. Doctor sues company over unethical marketing.
Charatan F
BMJ; 2002 May; 324(7348):1234. PubMed ID: 12028969
[No Abstract] [Full Text] [Related]
15. Warner-Lambert found guilty of promoting neurontin off label.
Larkin M
Lancet Neurol; 2004 Jul; 3(7):387. PubMed ID: 15228033
[No Abstract] [Full Text] [Related]
16. Confounding factors in off-label drug use.
Greenberg PE; Pike C; Sisitsky T
Health Aff (Millwood); 2012 Feb; 31(2):460; author reply 460. PubMed ID: 22323178
[No Abstract] [Full Text] [Related]
17. Clinical trial results, physicians, and insider trading.
Prentice RA
J Leg Med; 1999 Jun; 20(2):195-222. PubMed ID: 10407617
[No Abstract] [Full Text] [Related]
18. False Claims Act prosecution did not deter off-label drug use in the case of neurontin.
Kesselheim AS; Darby D; Studdert DM; Glynn R; Levin R; Avorn J
Health Aff (Millwood); 2011 Dec; 30(12):2318-27. PubMed ID: 22147859
[TBL] [Abstract][Full Text] [Related]
19. These two make quite a team.
Kassirer JP
Washington Post; 2004 Oct; ():B1, B5. PubMed ID: 15700368
[No Abstract] [Full Text] [Related]
20. Pros and cons of off-label promotion investigations and prosecutions.
Loucks MK
Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
[No Abstract] [Full Text] [Related]
[Next] [New Search]
